Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma
Rovingaile Kriska M. Ponce, Nicholas J. Thomas, Nam Q. Bui, Tadashi Kondo, Ross A. Okimoto
Rovingaile Kriska M. Ponce, Nicholas J. Thomas, Nam Q. Bui, Tadashi Kondo, Ross A. Okimoto
View: Text | PDF
Research Article Oncology

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma

  • Text
  • PDF
Abstract

CIC-DUX4 rearrangements define an aggressive and chemotherapy-insensitive subset of undifferentiated sarcomas. The CIC-DUX4 fusion drives oncogenesis through direct transcriptional upregulation of cell cycle and DNA replication genes. Notably, CIC-DUX4–mediated CCNE1 upregulation compromises the G1/S transition to confer a dependence on the G2/M cell cycle checkpoint. Through an integrative transcriptional and kinase activity screen using patient-derived specimens, we now show that CIC-DUX4 sarcomas depend on the G2/M checkpoint regulator WEE1 as part of an adaptive survival mechanism. Specifically, CIC-DUX4 sarcomas depended on WEE1 activity to limit DNA damage and unscheduled mitotic entry. Consequently, genetic or pharmacologic WEE1 inhibition in vitro and in vivo led to rapid DNA damage–associated apoptotic induction of patient-derived CIC-DUX4 sarcomas. Thus, we identified WEE1 as a vulnerability targetable by therapeutic intervention in CIC-DUX4 sarcomas.

Authors

Rovingaile Kriska M. Ponce, Nicholas J. Thomas, Nam Q. Bui, Tadashi Kondo, Ross A. Okimoto

×

Figure 2

CIC-DUX4 sarcomas depend on WEE1 for survival.

Options: View larger image (or click on image) Download as PowerPoint
CIC-DUX4 sarcomas depend on WEE1 for survival.
(A) CTG viability assay o...
(A) CTG viability assay of NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells treated with adavosertib. Error bars represent SEM; performed in duplicate. Crystal violet assay of NCC_CDS1_X1_C1 (B) and NCC_CDS2_C1 (C) cells comparing adavosertib (IC50 dose) and DMSO control. (D) Immunoblot analysis of NCC_CDS1_X1_C1 cells treated with adavosertib or DMSO control. Representative figure; performed in duplicate. Lysates were run on parallel gels. FL, full-length; Cl, cleaved. (E) Immunoblot analysis of NCC_CDS2_C1 cells treated with adavosertib or DMSO control. Representative figure; performed in duplicate. (F and G) Relative caspase-3/7 activity in NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells treated with adavosertib versus control. One-way ANOVA; performed in triplicate. (H and I) Immunoblot analysis of NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells expressing 2 independent WEE1 siRNAs. Representative figure; performed in duplicate. (J and K) CTG viability assay comparing 2 independent WEE1 siRNAs with scramble control in NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells. One-way ANOVA; performed in triplicate. (L and M) Viability assay comparing 2 independent WEE1 siRNAs with scramble control (siScrm) in NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells. One-way ANOVA; performed in duplicate. (N and O) Adavosertib IC50 dose in NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells expressing siCDK1, siCDK2, or siCDK1 and siCDK2. One-way ANOVA; performed in triplicate. (P) Relative viability comparing NCC_CDS1_X1_C1 and NCC_CDS2_C1 cells expressing CDK1WT or CDK1AF versus vector control. One-way ANOVA. Error bars represent SEM; performed in triplicate. (Q) Adavosertib IC50 dose in NCC_CDS2_C1 cells expressing siCCNE1 or siCtrl. Performed in triplicate. *P <0.001, Student’s t test. (R) Adavosertib IC50 dose in NCC_CDS1_X1_C1 cells expressing siCCNE1, siCCNE2, siCCNE1, and siCCNE2 compared with siCtrl; performed in triplicate. *P <0.001, 1-way ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts